Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, August 23, 2012 - Flucelvax


Submission Type: BLA    Submission ID: 125408/0    Office: OVRR
Influenza Vaccine (MDCK Cells)
Novartis Vaccines and Diagnostics, Inc.
Telecon Date/Time: 23-Aug-2012 12:20 PM        Initiated by FDA? Yes
Telephone Number:
Communication Categorie(s):
1. Advice
Telecon Summary:
Timing of Novartis' submission of the Trivalent Bulk samples
FDA Participants: None
Non-FDA Participants: Matthew Gollwitzer
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
In response to CBER’s August 17, 2012, Advice and Information Request, Novartis provided the following information regarding their proposed plans for submitting the FLUCELVAX trivalent bulk samples and Strain Change information:

Sample/Strain-change submission
Date of CBER Receipt
  •  1st lot of US Trivalent Bulk + Strain Change Submission
  •  2nd lot of US Trivalent Bulk
  • 3rd lot of US Trivalent Bulk

CBER indicated that these timelines were acceptable, but also stated that Novartis should be aware of the following:
  1. The first trivalent must arrive before the current approval target date, September 21, 2012.   If the first trivalent is not received by this date, then CBER may issue a Complete Response.
  2. Under the timeline you have provided below, CBER will plan to issue a Major Amendment once the first trivalent bulk arrives. 
  3. Assuming that a Major Amendment is issued, we will provide a new (non-PDUFA) target date for approval after the third trivalent bulk is received.
  4. If problems are encountered during CBER's testing, further delay in approval may be necessary.


Page Last Updated: 12/19/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English